...ilZyme AP Conjugate Stabilizer is an aqueous solut...her non-toxic stabilizing chemicals in a MES buffe... This product contains a combination of 0.02% met...preservative. StabilZyme AP Conjugate Stabilizer ...
Mouse Anti-Myoglobin Monoclonal Antibody, Biotin Conjugated, Clone 4E2 from Meridian Life Science, Inc.
... nonspecific binding is a problem in your applicat...vidin products as superior alternatives to avidin ...derivative that combines several key features to p... low nonspecific binding properties. NeutrAvidin d...
BlueView Nucleic Acid Stain from Sigma-Aldrich
Biology Products:(Date:11/5/2009)... training grant in the amount of $2,756,719 by the... Graduation Education and Research Training (IGERT...rded to Kent State. The grant, which is funded und...009, runs through 2014. , The grant funds an IGE...ource sensing (EARS). The purpose of the program i...
(Date:11/4/2009)... Long Beach and Riverside are responsible for a si...ma, and the true impact of air pollution and ship ...mated, according to researchers at the University ...h appears in an online edition of the American Jo...nt of all childhood asthma cases in Long Beach and...
(Date:11/4/2009)... the DNA codes, or genomes, of the famed fugu (or ...ome 10K Project, an international effort to build ...0 species of animals for conducting comparative st...d. , Participating in The Genome 10K project, de...ssue of the Journal of Heredity , are 70 leading ...
Breaking Biology News(10 mins):Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2USC study finds big air pollution impacts on local communities 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Re define 26apos 3BThank You 26apos 3B With Style and Value From Van 26apos 3Bs Gifts 59916 1Re define 26apos 3BThank You 26apos 3B With Style and Value From Van 26apos 3Bs Gifts 59916 2Committed Time and Personal Passion 3A Key Traits Among ABL 26apos 3Bs Award Finalists 59912 1Committed Time and Personal Passion 3A Key Traits Among ABL 26apos 3Bs Award Finalists 59912 2Committed Time and Personal Passion 3A Key Traits Among ABL 26apos 3Bs Award Finalists 59912 3Committed Time and Personal Passion 3A Key Traits Among ABL 26apos 3Bs Award Finalists 59912 4Dr Philip Katz Elected President of the American College of Gastroenterology 59908 1Dr Philip Katz Elected President of the American College of Gastroenterology 59908 2Dr Philip Katz Elected President of the American College of Gastroenterology 59908 3(Date:11/6/2009)...ING VALLEY, Calif., Nov. 6 Calbiot... a Small Business Innovative Research (SBIR) Phase...Material command. Under terms of the agreement, Ca...SRs) for the diagnosis of Dengue virus. ,, D...resents a major threat to military forces deployed...
(Date:11/5/2009)...THERSBURG, Md., Nov. 5 G...inancial results for the third quarter ended Septe...million ($0.04 per share) for the three months end....8 million ($0.08 per share) in the comparable qua...30, 2009, GenVec,s net loss was $14.1 million ($0....
(Date:11/5/2009)...ference Call on Thursday, November 5, 2009 at 4:30...R Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharma...SDAQ: OGXI ) today reported unaudited financial r... September 30, 2009 and reviewed the Company,s hig...ollowing consolidated results reflect the operatio...
(Date:11/5/2009)... DIEGO, CA, November 5, 2009 /PRNewswire-FirstCall...used on using proprietary taste receptor-based tec... the food, beverage, and ingredient supply industr...d financial results for the third quarter ended Se...the third quarter of 2009, compared to $4.0 millio...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14